They talk about their roles and reports and how Medidata handles clinical research. The verbal exchange covers topics ranging from patient engagement to technological advancements, highlighting the importance of human contact in clinical trials and the integration of data-driven responses to the patient experience.
LL: To begin with, could you introduce yourself and your functions at Medidata?
I’m Kelly McKee, vice president of decentralized clinical trials and patient registries at Medidata. My goal is to optimize site, patient, and sponsor experiences through generation solutions. I have over 20 years of experience working with giant pharmaceutical corporations prior to joining Medidata.
DB: Hi, I’m Daniel Braga, VP of EHR and Healthcare Solutions at Medidata. My role is to bridge the gap between healthcare and clinical research, leveraging metadata to connect those in disparate fields of the past. Prior to Medidata, I founded a startup in medical imaging interoperability.
LL: Let’s keep talking about your recent accomplishments. Dan, congratulations on winning the Site Innovation Award. Could you tell us more about your generation and how it is revolutionizing knowledge capture in clinical trials?
The generation we have developed aims to bridge the gap between physical care and clinical trials by enabling the seamless integration of electronic fitness record (EHR) knowledge into clinical trials. Historically, this procedure of accessing knowledge is time-consuming and error-prone. Our solution eliminates manual access to knowledge by offering sites with access to EHR knowledge, allowing them to simply click on applicable knowledge topics to fill out the required forms. Not only does this save time, but it also improves the quality of knowledge and reduces the rate of questions.
LL: It’s really extraordinary. Kelly, could you explain how this innovation contributes to patient participation and retention in clinical trials?
KM: Absolutely, Liza. Al streamlining the process of accessing information for sites, we ultimately improve the overall patient experience in clinical trials. Patients are no longer mere subjects offering knowledge; They actively participate in the study procedure. We’ve also implemented projects like live video tours to keep that contact private, especially during challenging times like the COVID-19 pandemic. Our purpose is to foster an engaging and supportive environment for patients on their trial journey.
Our purpose continues to be to make clinical trials less difficult for patients to locate and enroll, diversity trial populations, reduce site burden, and increase drug progression times.
LL: What are the common frustrations in the industry and how does Medidata deal with them?
KM: The main frustrations arise from the difficulty of locating and enrolling in trials, the lack of diversity in trial populations, and long drug progression times. We address those demanding situations by leveraging real-world knowledge to design patient populations, patient engagement, and streamline court processes.
DB: Human contact is imperative in clinical trials, and we are committed to treating patients as individuals, not just data. Our focus on patient feedback and engagement drives our efforts to test experiences.
LL: Can you play the generation’s role in improving the patient experience?
KM: Technology can be a difficult tool for the patient to enjoy in clinical trials. By combining highly tactile interactions with high-tech solutions, we are able to deliver personalized, easy-to-use experiences for attendees.
DB: For example, our live video visit initiative during the COVID-19 pandemic allowed patients to maintain private connections with trial staff, demonstrating the importance of human interaction alongside technological innovations.
LL: What are Medidata’s long-term instructions for revolutionizing clinical trials?
DB: We are exploring uses of cutting-edge data, such as artificial control arms, for patient experience and trial outcomes. Our goal remains to leverage technology to make clinical trials more accessible, diverse, and patient-centered.
KM: Ultimately, clinical trials are the long-term of medicine and we are committed to ensuring that patients have access to state-of-the-art remedies through elegant and engaging trial experiences.
LL: Dan, you discussed the importance of scalability in your solutions. How do you think your technologies are adaptable in other clinical trial environments?
DB: Scalability is key to our approach. We have designed our responses to be flexible and compatible with other healthcare systems and testing protocols. This allows us to serve a wide diversity of clients and serve diverse patient populations. In addition, our deep regulatory needs ensure that our technologies meet industry criteria while driving power and innovation.
LL: It’s a testament to your determination to advance the field of clinical research. Kelly spoke about the importance of diversity in patient recruitment. How does Medidata face this challenge?
KM: Diversity in clinical trials is ensuring that remedies are effective in varied populations. We use a multi-faceted approach, leveraging our features to help sponsors and CROs design inclusive recruitment strategies. This includes identifying sites with a varied history of patient recruitment. , engaging patients through education and empowerment initiatives, and partnering with organizations like Circuit Clinical to expand access to underrepresented communities.
LL: Do you have any other ideas or messages for long-term professionals entering the clinical trials sector?
DB: I’d like to inspire young professionals to embrace innovation and think big. The suite of clinical trials provides unprecedented opportunities to make a significant impact on global health. Don’t be afraid to challenge the prestige quo and pursue ambitious goals. Answers to complex problems.
KM: I echo Dan’s sentiments. Clinical trials are a dynamic and rewarding scenario that requires hobby and experience. Aspiring professionals will need to try to combine innovation with a deep understanding of regulatory and patient needs. Together, we can drive positive replacement and physical care outcomes for all.
More Promotional Features